Day: January 22, 2024

RESTON, Va., Jan. 22, 2024 (GLOBE NEWSWIRE) — Lightbridge Corporation (“Lightbridge”) (Nasdaq: LTBR), an advanced nuclear fuel technology company, today announced that Lightbridge President and CEO Seth Grae will participate in upcoming industry and media events. Tuesday, January 23, 8:30 am ET – BNN Bloomberg TV’s “The Street,” hosted by Paul Bagnell Lightbridge President and CEO Seth Grae will be interviewed on BNN Bloomberg TV’s “The Street”, hosted by Paul Bagnell. Mr. Grae will discuss the commitment of the United States, Canada, and other nations at COP28 to triple global nuclear power by 2050 and the importance of Lightbridge’s nuclear fuel technology to help achieve that goal, and will also discuss Canada’s plans for increasing nuclear power generation. A livestream of BNN Bloomberg can be accessed at https://www.bnnbloomberg.ca/live. Tuesday,...

Figure 1Sant Tolgoi Cu-Ni project is located in the Zavkhan Province approximately 1,100 km west of Ulaanbaatar, Mongolia. Project to located close to established infrastructure.Figure 2Sant Tolgoi Cu-Ni project covers two granted Exploration Licences XV-17774 (Oyut) and XV-21887 (Sant Tolgoi) a combined area of area of over 40km2.TORONTO, Jan. 22, 2024 (GLOBE NEWSWIRE) — Xanadu Mines Ltd (ASX: XAM, TSX: XAM) (Xanadu, XAM or the Company) is pleased to announce it has agreed a binding term sheet with STSM LLC (STSM) granting the right to earn up to 80% interest in two exploration licences XV-17774 (Oyut) and XV-21887 (Sant Tolgoi) located in the Zavkhan Province of Western Mongolia. These two licenses make up the Sant Tolgoi Project, which is considered highly prospective for discovery of new magmatic intrusion-related...

MONTREAL, Jan. 22, 2024 (GLOBE NEWSWIRE) — Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; “BRW” or the “Company”) is pleased to announce that it has started a Phase II drilling campaign at the Mirage project, located in the Eeyou-Istchee James Bay region of Quebec. The winter drill program is targeting extensions of known pegmatite dykes (MR-1 to MR-6) and new prospective outcrops that have yet to be drill-tested. The campaign will operate from a new BRW exploration camp located along the Trans-Taïga Road. Mr. Killian Charles, President and CEO of BRW, commented: “This will be an exciting 2024 start for BRW as we immediately commence a significant drill program at Mirage. The drilling campaign will aggressively target known dykes with wide step backs and deeper holes. It is our intention to rapidly demonstrate the potential...

CALGARY, Alberta, Jan. 22, 2024 (GLOBE NEWSWIRE) — Condor Energies Inc. (“Condor” or the “Company”) (TSX:CDR), a Canadian based energy transition company is pleased to announce that it has received a natural gas allocation (the “Gas Allocation”) from the Government of the Republic of Kazakhstan (Kazakhstan”). The Gas Allocation will be used as feed gas for the Company’s first modular liquefied natural gas (“LNG”) production facility. The feed gas will be liquefied to produce up to 350 Tonnes per day (210,000 gallons per day) of LNG, which can fuel approximately 125 rail locomotives or 215 large mine haul trucks (150 Tonne haul capacity). The CO2 emission reductions associated with using this LNG volume to displace diesel fuel equates to removing over 31,000 cars from service annually. The Company has also acquired 12 hectares of...

PDUFA Goal date is November 16, 2024 Company on track to submit a marketing authorization application to the European Medicines Agency (EMA) in the first half of 2024LONDON, Jan. 22, 2024 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for obecabtagene autoleucel (obe-cel) for patients with relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL). Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of November 16, 2024, a standard review timeline consistent with recently approved CAR T therapies. The FDA is not currently planning to hold an advisory...

Figure 1Plan view section of holes SB-2023-012 and 2023-023 drilling within the proposed Mustang Mine footprint.Figure 2Hole SB-2023-012 intersection on the BK Vein.Figure 3Hole SB-2023-023 intersections on the BK and Alhambra Veins.TORONTO, Jan. 22, 2024 (GLOBE NEWSWIRE) — Talisker Resources Ltd. (“Talisker” or the “Company”) (TSX:TSK | OTCQX:TSKFF) is pleased to announce additional high-grade drill results highlighted by 80.68 g/t Au over 2.20 metres within a broader interval of 28.58 g/t over 6.35 metres at its 100% owned flagship Bralorne Gold Project. Key Points:Talisker initiated resource conversion drilling on October 17, 2023 with 15,000 metres of planned drilling. Hole SB-2023-023 intersected 80.68 g/t Au over 2.20 metres within a broader interval of 28.58 g/t Au over 6.35 metres on the BK...

TORONTO, Jan. 22, 2024 (GLOBE NEWSWIRE) — Madison Metals Inc. (“Madison” or the “Company”) (CSE: GREN) (OTCQB: MMTLF) (FSE: 4EF0) is pleased to provide an update on its uranium forward sales agreement with Sanmiguel Capital Investment (Bahamas) Ltd., a financial advisory firm assisting with the administration. Since November 2023, Madison Metals has successfully received funds for its first tranche of the Company’s forward sales agreement, at an average price of US$68 per lb. This achievement underscores the uranium agreement’s effectiveness in securing favorable pricing, well above the contractual established US$45 price floor. As there is no price ceiling, Madison’s forward sales agreement provides upside potential for advantageous pricing as the market continues to surge. The significant flexibility of the forward sales agreement...

ZUG, Switzerland, Jan. 22, 2024 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Investigational New Drug (IND) application for deucrictibant for the prophylactic treatment of HAE attacks following review of data from a 26-week rodent toxicology study. “The lift of the clinical hold in the U.S. enables us to progress the global development of deucrictibant for long-term prophylaxis, including resuming the open-label portion of CHAPTER-1, our Phase 2 proof-of-concept study of deucrictibant for the prevention of HAE attacks, in the U.S.,” said Berndt Modig, Chief Executive Officer of Pharvaris. “We are...